Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) rose 2.5% on Monday . The company traded as high as $24.40 and last traded at $24.01. Approximately 80,622 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 293,426 shares. The stock had previously closed at $23.43.
Analyst Ratings Changes
KMTS has been the topic of a number of research reports. Piper Sandler started coverage on shares of Kestra Medical Technologies in a report on Monday. They set an "overweight" rating and a $27.00 target price on the stock. Wolfe Research started coverage on Kestra Medical Technologies in a research note on Monday. They issued an "outperform" rating and a $29.00 price objective on the stock. Bank of America began coverage on Kestra Medical Technologies in a research note on Monday. They set a "buy" rating and a $30.00 target price for the company. Stifel Nicolaus started coverage on Kestra Medical Technologies in a research report on Monday. They issued a "buy" rating and a $28.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Kestra Medical Technologies in a research report on Monday. They set a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $27.67.
Get Our Latest Report on KMTS
Kestra Medical Technologies Price Performance
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
